The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across the entire world.Even though several COVID-19 vaccines are currently in distribution worldwide,with others in the pipeline,treatment m...The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across the entire world.Even though several COVID-19 vaccines are currently in distribution worldwide,with others in the pipeline,treatment modalities lag behind.Accordingly,researchers have been working hard to understand the nature of the virus,its mutant strains,and the pathogenesis of the disease in order to uncover possible drug targets and effective therapeutic agents.As the research continues,we now know the genome structure,epidemiological and clinical features,and pathogenic mechanism of SARS-CoV-2.Here,we summarized the potential therapeutic targets involved in the life cycle of the virus.On the basis of these targets,small-molecule prophylactic and therapeutic agents have been or are being developed for prevention and treatment of SARS-CoV-2 infection.展开更多
The outbreaks of severe acute respiratory syndrome(SARS)and Coronavirus Disease 2019(COVID-19)caused by SARS-CoV and SARS-CoV-2,respectively,have posed severe threats to global public health and the economy.Treatment ...The outbreaks of severe acute respiratory syndrome(SARS)and Coronavirus Disease 2019(COVID-19)caused by SARS-CoV and SARS-CoV-2,respectively,have posed severe threats to global public health and the economy.Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies(NMAbs).Scientists have screened neutralizing antibodies using the virus receptor-binding domain(RBD)as an antigen,indicating that RBD contains multiple conformational neutralizing epitopes,which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses.This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.展开更多
Dear Editor,Duck virus hepatitis(DVH)is a significant concern in the duck industry as the disease causes a highly contagious infection in young ducklings that is often associated with liver necrosis,hemorrhage,and hig...Dear Editor,Duck virus hepatitis(DVH)is a significant concern in the duck industry as the disease causes a highly contagious infection in young ducklings that is often associated with liver necrosis,hemorrhage,and high mortality(Yugo et al.2016).Duck hepatitis virus(DHV)was first described in1949 on Long Island in the United States.Subsequent,outbreaks have been reported in England,Canada,Germany,Japan and elsewhere(Toth 1969).展开更多
基金This work was supported by grants from the National Natural Science Foundation of China(81974302 and 82041025)the Program for“333 Talents Project”of Hebei Province(A202002003,China)Science and Technology Project of Hebei Education Department(QN2021071,China).
文摘The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across the entire world.Even though several COVID-19 vaccines are currently in distribution worldwide,with others in the pipeline,treatment modalities lag behind.Accordingly,researchers have been working hard to understand the nature of the virus,its mutant strains,and the pathogenesis of the disease in order to uncover possible drug targets and effective therapeutic agents.As the research continues,we now know the genome structure,epidemiological and clinical features,and pathogenic mechanism of SARS-CoV-2.Here,we summarized the potential therapeutic targets involved in the life cycle of the virus.On the basis of these targets,small-molecule prophylactic and therapeutic agents have been or are being developed for prevention and treatment of SARS-CoV-2 infection.
基金supported by grants from the National Natural Science Foundation of China(81974302,82041025,and 81630090)a starting grant from Hebei Agricultural University(YJ201843).
文摘The outbreaks of severe acute respiratory syndrome(SARS)and Coronavirus Disease 2019(COVID-19)caused by SARS-CoV and SARS-CoV-2,respectively,have posed severe threats to global public health and the economy.Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies(NMAbs).Scientists have screened neutralizing antibodies using the virus receptor-binding domain(RBD)as an antigen,indicating that RBD contains multiple conformational neutralizing epitopes,which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses.This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.
基金supported by the National Natural Science Foundation of China Grants 31300141(to CCM)Shanghai Key Laboratory of Veterinary Biotechnology Grants klab201702(to CCM)
文摘Dear Editor,Duck virus hepatitis(DVH)is a significant concern in the duck industry as the disease causes a highly contagious infection in young ducklings that is often associated with liver necrosis,hemorrhage,and high mortality(Yugo et al.2016).Duck hepatitis virus(DHV)was first described in1949 on Long Island in the United States.Subsequent,outbreaks have been reported in England,Canada,Germany,Japan and elsewhere(Toth 1969).
